Privia Health Group Elects Opella Ernest, M.D. to Board

What Happened
Privia Health Group, Inc. (PRVA) filed a Form 8-K reporting that on August 12, 2026 its Board elected Opella Ernest, M.D. as a Class III director, with the appointment effective September 1, 2026. Dr. Ernest was also named a member of the Board’s Compliance Committee effective September 1. The Board has determined she is independent under Nasdaq standards. The company issued a press release on August 18, 2026 announcing the appointment.

Key Details

• Election date: August 12, 2026; effective date: September 1, 2026.
• Committee role: appointed to the Board’s Compliance Committee effective Sept. 1, 2026.
• Independence: Board determined Dr. Ernest is independent under Nasdaq rules.
• Compensation: will receive the standard annual cash retainer under the Non-Employee Director Compensation Program and an annual restricted stock unit (RSU) equity grant under the 2021 Omnibus Incentive Plan with a grant date fair value of $200,000; the initial RSU grant will be pro‑rated through the next annual meeting.
• No related-party arrangements or transactions requiring disclosure under Item 404 were reported.

Why It Matters
This 8-K documents a governance change — adding an independent director with a seat on the Compliance Committee — which can affect board oversight and compliance oversight capacity. Compensation is typical for non-employee directors (cash retainer plus equity) and the filing confirms no disclosed related-party interests, which is relevant to investors monitoring governance and potential conflicts of interest. The filing is Item 5.02 on the 8-K and includes a press release as an exhibit.